Compounds > 5,12-dihydroxy-6,8,14-eicosatrienoic acid
Page last updated: 2024-12-11
5,12-dihydroxy-6,8,14-eicosatrienoic acid
Description
5,12-dihydroxy-6,8,14-eicosatrienoic acid: RN given refers to (S-(R*,R*-(Z,E,Z)))-isomer; RN for cpd without isomeric designation not avail 8/90 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
10,11-dihydroleukotriene B4 : A leukotriene obtained by formal dehydrogenation of the 10,11-double bond in leukotriene B4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
Synonyms (10)
Synonym |
10,11-dihydroleukotriene b4 |
5,12-dihydroxy-6,8,14-eicosatrienoic acid |
CHEBI:134444 |
120904-46-3 |
(5s,6z,8e,12s,14z)-5,12-dihydroxyicosa-6,8,14-trienoic acid |
dhltb4 |
10,11-dihydro-ltb4 |
6,8,14-eicosatrienoic acid, 5,12-dihydroxy-, (s-(r*,r*-(z,e,z)))- |
(5s,6z,8e,12s,14z)-5,12-dihydroxy-6,8,14-eicosatrienoic acid |
DTXSID301183688 |
Roles (2)
Role | Description |
human xenobiotic metabolite | Any human metabolite produced by metabolism of a xenobiotic compound in humans. |
human urinary metabolite | Any metabolite (endogenous or exogenous) found in human urine samples. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (4)
Class | Description |
dihydroxy monocarboxylic acid | Any hydroxy monocarboxylic acid carrying at least two hydroxy groups. |
leukotriene | Any icosanoid from that family of C20 polyunsaturated fatty acids and their derivatives generated by leukocytes from arachidonic acid, each member having four double bonds of which three are conjugated. |
long-chain fatty acid | A fatty acid with a chain length ranging from C13 to C22. |
hydroxy polyunsaturated fatty acid | Any polyunsaturated fatty acid carrying one or more hydroxy substituents. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (80.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.66
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.66 (24.57) | Research Supply Index | 1.79 (2.92) | Research Growth Index | 4.45 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |